Aquinox Announces Second Quarter 2017 Financial Results

VANCOUVER, British Columbia, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today provided a corporate update and reported financial results for the second quarter ending June 30, 2017.

“With more than one hundred trial sites initiated, enrollment in LEADERSHIP 301 is now on pace with expectations and we anticipate reporting top-line data in the third quarter of 2018,” said David Main, President & CEO of Aquinox. “After a thorough examination of numerous potential disease states, we also are pleased to announce the expansion of our rosiptor (AQX-1125) clinical development program with the planned initiation of a Phase 2 clinical trial in Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) and expect patient enrollment to commence in the first quarter of 2018.”

Back to news